APA (7th ed.) Citation

Zhang, Q., Wang, M., Li, Y., Zhang, H., Wang, Y., Chen, X., . . . Xu, Y. Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab (a PD-1 inhibitor) plus nab-paclitaxel followed by epirubicin/cyclophosphamide for triple-negative breast cancer: A phase 2 TREND trial. Nature Publishing Group.

Chicago Style (17th ed.) Citation

Zhang, Qiang, et al. Efficacy, Safety and Exploratory Analysis of Neoadjuvant Tislelizumab (a PD-1 Inhibitor) Plus Nab-paclitaxel Followed by Epirubicin/cyclophosphamide for Triple-negative Breast Cancer: A Phase 2 TREND Trial. Nature Publishing Group.

MLA (9th ed.) Citation

Zhang, Qiang, et al. Efficacy, Safety and Exploratory Analysis of Neoadjuvant Tislelizumab (a PD-1 Inhibitor) Plus Nab-paclitaxel Followed by Epirubicin/cyclophosphamide for Triple-negative Breast Cancer: A Phase 2 TREND Trial. Nature Publishing Group.